INIGEM   23989
INSTITUTO DE INMUNOLOGIA, GENETICA Y METABOLISMO
Unidad Ejecutora - UE
artículos
Título:
The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial
Autor/es:
DE LAPERTOSA, SILVIA BEATRIZ GORBAN; SAUQUE-REYNA, LEOBARDO; HARDY, ELISE; FRECHTEL, GUSTAVO
Revista:
DIABETES RESEARCH AND CLINICAL PRACTICE
Editorial:
ELSEVIER IRELAND LTD
Referencias:
Año: 2016 vol. 122 p. 38 - 45
ISSN:
0168-8227
Resumen:
Aims Socioeconomic changes in Latin American countries have led to an increased prevalence of type 2 diabetes (T2D). We examined the effects of exenatide twice daily (BID) or insulin lispro, each added to insulin glargine, in Latin American patients with T2D. Methods This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N = 114). Patients with glycated hemoglobin (HbA1c) of 7.0?10.0% (53?86 mmol/mol) after 12 weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin. Results After 30 weeks, addition of exenatide BID or insulin lispro resulted in significant (P